EMA restricts use of prostate cancer medicine Xofigo

View source ↗

Summary

The EMA restricts the use of Xofigo (radium-223 dichloride) for prostate cancer due to safety concerns and updated recommendations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)